Accurate Diagnosis, Evidence-Based Treatment, and Long-Term Management in Persons of Color with ADPremiere Date: Tuesday, September 21, 2021
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, September 21, 2022
Note: Credit Is No Longer Available
|Zelma C. Chiesa Fuxench, MD, MSCE
Assistant Professor of Dermatology
Department of Dermatology
University of Pennsylvania Perelman School of Medicine
|Candrice Heath, MD
Assistant Professor of Dermatology
Lewis Katz School of Medicine at Temple University
Atopic dermatitis (AD) can appear differently across various skin tones; there are racial and ethnic differences in its epidemiology, pathophysiology, clinical presentation, and treatment. It is imperative that health care professionals improve their knowledge on the varying presentations and risk factors in patients of color in order to appropriately screen and treat these patients.
In this CME Outfitters Live and OnDemand, expert faculty will discuss recommended screening for AD among patients of color, the impact of racial disparities on patients with AD, and the application of optimal strategies for managing patients with AD.
At the end of this CE activity, participants should be able to:
- Integrate appropriate tools in the assessment of AD in patients of color.
- Apply the latest evidence for the optimal management of AD based on disease severity in collaboration with patients.
- Develop a long-term management plan in patients with moderate to severe AD that includes routine assessment and monitoring.
Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals
Primary care physicians, dermatologists, nurse practitioners, PAs, nurses, and pharmacists
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
ABIM MOC:Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Chiesa-Fuxench reports that she receives grants from the Dermatology Foundation Career Development Award (PI). She receives research support from LEO Pharma Inc.; Menlo Therapeutics; Sanofi-Regeneron Pharmaceuticals Inc.; and Vanda Pharmaceuticals Inc. She consults for AbbVie Inc.; Incyte; LEO Pharma Inc.; and Sanofi-Regeneron Pharmaceuticals Inc.
Dr. Heath reports that she consults for Cassiopea, Inc.; Leo Pharma Inc.; and Pfizer Inc.
Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).